LI
LIC MF Healthcare Fund Direct Growth
Latest NAV
+13.76% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
1.42%
AUM
₹103 Cr
Min SIP
₹200
Min lump sum
₹5,000
1Y
+13.76%
3Y (ann.)
+20.88%
5Y (ann.)
+12.01%
Launched
Feb 2019
Where the NAV sits & how risky it is
₹36.41
52-week range
at 77%
₹36.41
Low 29 Jan 2026₹29.62
High 31 Aug 2026₹38.47
Risk level
Very High
Low
Very high
NAV history
08 Mar 2019
Since inception
01 Oct 2026
Returns by period
1W
-4.25%
1M
-4.36%
3M
+3.85%
6M
+21.29%
1Y
+13.76%
3Y
+20.88%
5Y
+12.01%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹200
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 92.92%
Cash & other 7.50%
Sector split
Country split
Top 5 hold 36.8%
Top 10 hold 58.4%
29 equity holdings
Equity holdings
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
10.61%
|
+4.66% |
| 2 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
7.56%
|
+2.01% |
| 3 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
6.63%
|
+18.83% |
| 4 | Torrent Pharmaceuticals
INE685A01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.51%
|
+15.54% |
| 5 | Neuland Laboratories
INE794A01010 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.49%
|
+11.79% |
| 6 | Navin Fluorine International
INE048G01026 |
Basic Materials Chemicals |
India |
5.38%
|
+15.94% |
| 7 | Aurobindo Pharma
INE406A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.98%
|
+22.72% |
| 8 | Fortis Healthcare
INE061F01013 |
Healthcare Medical Care Facilities |
India |
4.49%
|
+11.89% |
| 9 | Gland Pharma
INE068V01023 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.55%
|
+30.53% |
| 10 | Zydus Life Science
INE010B01027 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.15%
|
+18.95% |
About this scheme
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. However there can be no assurance that the investment objective under the scheme will be realized.
Fund manager(s): Sudhanshu Asthana, Dhaval Sangoi
Exit load: Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
28 Feb 2019
Lump-sum min
₹5,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 107.8 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 19.6 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 16.8 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 16.8 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 15.5 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 15.4 pts ahead of this fund